In the article beginning on page 2391 in the 19 May 2016 issue, there are errors in the text and in Tables 1 and 10.

In Table 1 (page 2392), the entry “Blastic plasmacytoid dendritic cell neoplasm” was omitted. The corrected table is shown below.

Table 1

WHO classification of myeloid neoplasms and acute leukemia

WHO myeloid neoplasm and acute leukemia classification
Myeloproliferative neoplasms (MPN) 
 Chronic myeloid leukemia (CML), BCR-ABL1+ 
 Chronic neutrophilic leukemia (CNL) 
 Polycythemia vera (PV) 
 Primary myelofibrosis (PMF) 
  PMF, prefibrotic/early stage 
  PMF, overt fibrotic stage 
 Essential thrombocythemia (ET) 
 Chronic eosinophilic leukemia, not otherwise specified (NOS) 
 MPN, unclassifiable 
Mastocytosis 
Myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRA, PDGFRB, or FGFR1, or with PCM1-JAK2 
 Myeloid/lymphoid neoplasms with PDGFRA rearrangement 
 Myeloid/lymphoid neoplasms with PDGFRB rearrangement 
 Myeloid/lymphoid neoplasms with FGFR1 rearrangement 
Provisional entity: Myeloid/lymphoid neoplasms with PCM1-JAK2 
Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) 
 Chronic myelomonocytic leukemia (CMML) 
 Atypical chronic myeloid leukemia (aCML), BCR-ABL1 
 Juvenile myelomonocytic leukemia (JMML) 
 MDS/MPN with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) 
 MDS/MPN, unclassifiable 
Myelodysplastic syndromes (MDS) 
 MDS with single lineage dysplasia 
 MDS with ring sideroblasts (MDS-RS) 
  MDS-RS and single lineage dysplasia 
  MDS-RS and multilineage dysplasia 
 MDS with multilineage dysplasia 
 MDS with excess blasts 
 MDS with isolated del(5q) 
 MDS, unclassifiable 
Provisional entity: Refractory cytopenia of childhood 
Myeloid neoplasms with germ line predisposition 
Acute myeloid leukemia (AML) and related neoplasms 
 AML with recurrent genetic abnormalities 
  AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1 
  AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11 
  APL with PML-RARA 
  AML with t(9;11)(p21.3;q23.3);MLLT3-KMT2A 
  AML with t(6;9)(p23;q34.1);DEK-NUP214 
  AML with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM 
  AML (megakaryoblastic) with t(1;22)(p13.3;q13.3);RBM15-MKL1 
  Provisional entity: AML with BCR-ABL1 
  AML with mutated NPM1 
  AML with biallelic mutations of CEBPA 
  Provisional entity: AML with mutated RUNX1 
 AML with myelodysplasia-related changes 
 Therapy-related myeloid neoplasms 
 AML, NOS 
  AML with minimal differentiation 
  AML without maturation 
  AML with maturation 
  Acute myelomonocytic leukemia 
  Acute monoblastic/monocytic leukemia 
  Pure erythroid leukemia 
  Acute megakaryoblastic leukemia 
  Acute basophilic leukemia 
  Acute panmyelosis with myelofibrosis 
 Myeloid sarcoma 
 Myeloid proliferations related to Down syndrome 
  Transient abnormal myelopoiesis (TAM) 
  Myeloid leukemia associated with Down syndrome 
Blastic plasmacytoid dendritic cell neoplasm 
Acute leukemias of ambiguous lineage 
 Acute undifferentiated leukemia 
 Mixed phenotype acute leukemia (MPAL) with t(9;22)(q34.1;q11.2); BCR-ABL1 
 MPAL with t(v;11q23.3); KMT2A rearranged 
 MPAL, B/myeloid, NOS 
 MPAL, T/myeloid, NOS 
B-lymphoblastic leukemia/lymphoma 
 B-lymphoblastic leukemia/lymphoma, NOS 
 B-lymphoblastic leukemia/lymphoma with recurrent genetic abnormalities 
 B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2);BCR-ABL1 
 B-lymphoblastic leukemia/lymphoma with t(v;11q23.3);KMT2A rearranged 
 B-lymphoblastic leukemia/lymphoma with t(12;21)(p13.2;q22.1); ETV6-RUNX1 
 B-lymphoblastic leukemia/lymphoma with hyperdiploidy 
 B-lymphoblastic leukemia/lymphoma with hypodiploidy 
 B-lymphoblastic leukemia/lymphoma with t(5;14)(q31.1;q32.3) IL3-IGH 
 B-lymphoblastic leukemia/lymphoma with t(1;19)(q23;p13.3);TCF3-PBX1 
Provisional entity: B-lymphoblastic leukemia/lymphoma, BCR-ABL1–like 
Provisional entity: B-lymphoblastic leukemia/lymphoma with iAMP21 
T-lymphoblastic leukemia/lymphoma 
Provisional entity: Early T-cell precursor lymphoblastic leukemia 
Provisional entity: Natural killer (NK) cell lymphoblastic leukemia/lymphoma 
WHO myeloid neoplasm and acute leukemia classification
Myeloproliferative neoplasms (MPN) 
 Chronic myeloid leukemia (CML), BCR-ABL1+ 
 Chronic neutrophilic leukemia (CNL) 
 Polycythemia vera (PV) 
 Primary myelofibrosis (PMF) 
  PMF, prefibrotic/early stage 
  PMF, overt fibrotic stage 
 Essential thrombocythemia (ET) 
 Chronic eosinophilic leukemia, not otherwise specified (NOS) 
 MPN, unclassifiable 
Mastocytosis 
Myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRA, PDGFRB, or FGFR1, or with PCM1-JAK2 
 Myeloid/lymphoid neoplasms with PDGFRA rearrangement 
 Myeloid/lymphoid neoplasms with PDGFRB rearrangement 
 Myeloid/lymphoid neoplasms with FGFR1 rearrangement 
Provisional entity: Myeloid/lymphoid neoplasms with PCM1-JAK2 
Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) 
 Chronic myelomonocytic leukemia (CMML) 
 Atypical chronic myeloid leukemia (aCML), BCR-ABL1 
 Juvenile myelomonocytic leukemia (JMML) 
 MDS/MPN with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) 
 MDS/MPN, unclassifiable 
Myelodysplastic syndromes (MDS) 
 MDS with single lineage dysplasia 
 MDS with ring sideroblasts (MDS-RS) 
  MDS-RS and single lineage dysplasia 
  MDS-RS and multilineage dysplasia 
 MDS with multilineage dysplasia 
 MDS with excess blasts 
 MDS with isolated del(5q) 
 MDS, unclassifiable 
Provisional entity: Refractory cytopenia of childhood 
Myeloid neoplasms with germ line predisposition 
Acute myeloid leukemia (AML) and related neoplasms 
 AML with recurrent genetic abnormalities 
  AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1 
  AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11 
  APL with PML-RARA 
  AML with t(9;11)(p21.3;q23.3);MLLT3-KMT2A 
  AML with t(6;9)(p23;q34.1);DEK-NUP214 
  AML with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM 
  AML (megakaryoblastic) with t(1;22)(p13.3;q13.3);RBM15-MKL1 
  Provisional entity: AML with BCR-ABL1 
  AML with mutated NPM1 
  AML with biallelic mutations of CEBPA 
  Provisional entity: AML with mutated RUNX1 
 AML with myelodysplasia-related changes 
 Therapy-related myeloid neoplasms 
 AML, NOS 
  AML with minimal differentiation 
  AML without maturation 
  AML with maturation 
  Acute myelomonocytic leukemia 
  Acute monoblastic/monocytic leukemia 
  Pure erythroid leukemia 
  Acute megakaryoblastic leukemia 
  Acute basophilic leukemia 
  Acute panmyelosis with myelofibrosis 
 Myeloid sarcoma 
 Myeloid proliferations related to Down syndrome 
  Transient abnormal myelopoiesis (TAM) 
  Myeloid leukemia associated with Down syndrome 
Blastic plasmacytoid dendritic cell neoplasm 
Acute leukemias of ambiguous lineage 
 Acute undifferentiated leukemia 
 Mixed phenotype acute leukemia (MPAL) with t(9;22)(q34.1;q11.2); BCR-ABL1 
 MPAL with t(v;11q23.3); KMT2A rearranged 
 MPAL, B/myeloid, NOS 
 MPAL, T/myeloid, NOS 
B-lymphoblastic leukemia/lymphoma 
 B-lymphoblastic leukemia/lymphoma, NOS 
 B-lymphoblastic leukemia/lymphoma with recurrent genetic abnormalities 
 B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2);BCR-ABL1 
 B-lymphoblastic leukemia/lymphoma with t(v;11q23.3);KMT2A rearranged 
 B-lymphoblastic leukemia/lymphoma with t(12;21)(p13.2;q22.1); ETV6-RUNX1 
 B-lymphoblastic leukemia/lymphoma with hyperdiploidy 
 B-lymphoblastic leukemia/lymphoma with hypodiploidy 
 B-lymphoblastic leukemia/lymphoma with t(5;14)(q31.1;q32.3) IL3-IGH 
 B-lymphoblastic leukemia/lymphoma with t(1;19)(q23;p13.3);TCF3-PBX1 
Provisional entity: B-lymphoblastic leukemia/lymphoma, BCR-ABL1–like 
Provisional entity: B-lymphoblastic leukemia/lymphoma with iAMP21 
T-lymphoblastic leukemia/lymphoma 
Provisional entity: Early T-cell precursor lymphoblastic leukemia 
Provisional entity: Natural killer (NK) cell lymphoblastic leukemia/lymphoma 

On page 2393, in line 5 of the first paragraph in the right column, “t(8;9)(p22;q24.1);PCM1-JAK2” should read, “t(8;9)(p22;p24.1);PCM1-JAK2.”

In Table 10 (page 2397), column 2, in the information for PCM1-JAK2, “Often presents with T-LBL or B-ALL” should read “Rarely presents with T-LBL or B-ALL.” In column 3, in the information for PDGFRB, “t(5;12)(q31∼33;p12)” should read “t(5;12)(q32;p13.2).” In column 3, in the information for FGFR1, “Translocations of 8p11” should read “Translocations of 8p11.2.” The corrected table is shown below.

Table 10

Molecular genetic abnormalities in myeloid/lymphoid neoplasms associated with eosinophilia

DiseasePresentationGeneticsTreatment
PDGFRA Eosinophilia Cryptic deletion at 4q12 Respond to TKI 
↑Serum tryptase FIP1L1-PDGFRA, at least 66 other partners 
↑Marrow mast cells 
PDGFRB Eosinophilia t(5;12)(q32;p13.2) ETV6-PDGFRB, at least 25 other partners Respond to TKI 
Monocytosis mimicking CMML 
FGFR1 Eosinophilia Translocations of 8p11.2 Poor prognosis; do not respond to TKI 
Often presents with T-ALL or AML FGFR1-various partners 
PCM1-JAK2 Eosinophilia t(8;9)(p22;p24.1) PCM1-JAK2 May respond to JAK2 inhibitors 
Rarely presents with T-LBL or B-ALL 
Bone marrow shows left-shifted erythroid predominance and lymphoid aggregates 
DiseasePresentationGeneticsTreatment
PDGFRA Eosinophilia Cryptic deletion at 4q12 Respond to TKI 
↑Serum tryptase FIP1L1-PDGFRA, at least 66 other partners 
↑Marrow mast cells 
PDGFRB Eosinophilia t(5;12)(q32;p13.2) ETV6-PDGFRB, at least 25 other partners Respond to TKI 
Monocytosis mimicking CMML 
FGFR1 Eosinophilia Translocations of 8p11.2 Poor prognosis; do not respond to TKI 
Often presents with T-ALL or AML FGFR1-various partners 
PCM1-JAK2 Eosinophilia t(8;9)(p22;p24.1) PCM1-JAK2 May respond to JAK2 inhibitors 
Rarely presents with T-LBL or B-ALL 
Bone marrow shows left-shifted erythroid predominance and lymphoid aggregates 

↑, Increased.

The errors have been corrected in the online version, which now differs from the print version.